PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26223F0437Balversa tablets — Janssen Biotech, Inc

Janssen Biotech, Inc holds $1.5M across 46 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79719D0217. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Janssen Biotech, Inc

Recipient

Sep 30, 2023

PoP end

$27K

Obligated

$102K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Janssen Biotech, Inc — $90

Contract facts

Federal

Contract number36C26223F0437

Also listed as36C262-23-F-0437

Also listed as36F79719D0217-36C26223F0437

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentJanssen Biotech, Inc

CAGE0MJM1

UEINVYMGFA53MN7

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0217

Place of performanceCARROLLTON TX

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMay 15, 2023

PoP end (current)Sep 30, 2023

Obligated$27K

Current value$102K

Potential value$102K

BALVERSA TABLETS is a federal award for 262-Network Contract Office 22 (36C262) held by Janssen Biotech, Inc. Estimated value $102K ($27K obligated). Current period of performance ends Sep 30, 2023. Last award drew 1 bidder. Place of performance: CARROLLTON TX.

Recompete timing

Public

● Past PoP end (1056 days ago)

Current PoP ended Sep 30, 2023 (1056 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Janssen Biotech, Inc — $1.5M obligated across 46 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$1.5M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C25926F0264

EMERGENCY PHARMACY CARVYKTI FOR RMR

$385K

Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26223F0437?

36C26223F0437 (Balversa tablets) is a 262-Network Contract Office 22 (36C262) award with a potential value of $102K, currently held by Janssen Biotech, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-23-F-0437?

36C262-23-F-0437 is the dashed form of PIID 36C26223F0437 (Balversa tablets), held by Janssen Biotech, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26223F0437?

262-Network Contract Office 22 (36C262) awarded 36C26223F0437 to Janssen Biotech, Inc (potential $102K).

Who is the incumbent on 36C26223F0437?

Janssen Biotech, Inc is the incumbent with $1.5M across 46 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2023.

When does Janssen Biotech, Inc’s 36C26223F0437 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 11, 2026 · refreshed monthlyLatest procurement action Sep 28, 2023